Molecular physiology of urate transport

Physiology

Volumn 20, Issue 2, 2005, Pages 125-133

  Hediger, Matthias A ^a   Johnson, Richard J ^b   Miyazaki, Hiroki ^c   Endou, Hitoshi ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; CORTICOSTEROID; GALECTIN; MULTIDRUG RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PURINE; TAMM HORSFALL GLYCOPROTEIN; URIC ACID;

DIETARY INTAKE; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOURICEMIA; NITROGEN METABOLISM; PURINE METABOLISM; PURINE SYNTHESIS; REVIEW; URIC ACID BLOOD LEVEL; URIC ACID STONE; URIC ACID URINE LEVEL;

EID: 18244387733     PISSN: 15489213     EISSN: None     Source Type: Journal    
DOI: 10.1152/physiol.00039.2004     Document Type: Review

References (59)

1. Ames BN, Cathcart R, Schwiers E, and Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78: 6858-6862, 1981.
2. Anzai N, Miyazaki H, Noshiro R, Khamdang S, Chairoungdua A, Shin HJ, Enomoto A, Sakamoto S, Hirata T, Tomita K, Kanai Y, and Endou H. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C-terminal. J Biol Chem 279: 45942-45950, 2004.
3. Bachmann S, Mutig K, Bates J, Welker P, Geist B, Gross V, Luft FC, Alenina N, Bader M, Thiele BJ, Prasadan K, Raffi HS, and Kumar S. Renal effects of Tamm-Horsfall protein (uromodulin) deficiency in mice. Am J Physiol Renal Physiol (November 2, 2004). doi:10.1152/ajprenal.00143.2004.
4. Bakhiya A, Bahn A, Burckhardt G, and Wolff N. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 13: 249-256, 2003.
5. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med 14: 615-631, 1993.
6. Bleyer AJ, Woodard AS, Shihabi Z, Sandhu J, Zhu H, Satko SG, Weller N, Deterding E, McBride D, Gorry MC, Xu L, Ganier D, and Hart TC. Clinical characterization of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene. Kidney Int 64: 36-42, 2003.
7. Campion E, Glynn R, and DeLabry L. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 82: 421-426, 1987.
8. Cappuccio FP, Iacone R, and Strazzullo P. Serum uric acid and proximal sodium excretion: an independent association in man (the Olivetti Study). J Hypertens Suppl 9: S280-S281, 1991.
9. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, and Endou H. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59: 1277-1286, 2001.
10. Custer M, Spindler B, Verrey F, Murer H, and Biber J. Identification of a new gene product (diphor-1) regulated by dietary phosphate. Am J Physiol Renal Physiol 273: F801-F806, 1997.
11. Cutler RG. Antioxidants and aging. Am J Clin Nutr 53: 373S-379S, 1991.
12. Dantzler WH. Comparative aspects of renal urate transport. Kidney Int 49: 1549-1551, 1996.
13. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, and Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 105: 2619-2624, 2002.
14. Emmerson BT. Effect of oral fructose on urate production. Ann Rheum Dis 33: 276-280, 1974.
15. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, and Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417: 447-452, 2002.
16. Faller J and Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med 307: 1598-1602, 1982.
17. Feig DI and Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 42: 247-252, 2003.
18. Feig DI, Nakagawa T, Karumanchi SA, Oliver WJ, Kang DH, Finch J, and Johnson RJ. Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 66: 281-287, 2004.
19. Fox IH and Kelley WN. Studies on the mechanism of fructose-induced hyperuricemia in man. Metabolism 21: 713-721, 1972.
20. Hallfrisch J. Metabolic effects of dietary fructose. FASEB J 4: 2652-2660, 1990.
21. Han L, Kanellis J, Li P, Feng L, Nakagawa T, Kooyer S, Watanabe S, Ohashi R, Kahm AM, and Johnson RJ. The evidence for a functional organic anion transporter in vascular smooth muscle cells (Abstract). J Am Soc Nephrol 13: 329A, 2002.
22. Heuckenkamp PU and Zollner N. Fructose-induced hyperuricaemia. Lancet 1: 808-809, 1971.
23. Hosoyamada M, Ichida K, Enomoto A, Hosoya T, and Endou H. Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol 15: 261-268, 2004.
24. Hung AY and Sheng M. PDZ domains: structural modules for protein complex assembly. J Biol Chem 277: 5699-5702, 2002.
25. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, and Hosoya T. Clinical and molecular analysis of patients with renal hypouricemia in Japan - influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 15: 164-173, 2004.
26. Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T, and Endou H. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 63: 143-155, 2003.
27. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, and Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 41: 1183-1190, 2003.
28. Johnson RJ, Titte S, Cade JR, Rideout BA, and Oliver WJ. Uric acid, evolution, and primitive cultures. Semin Nephrol 25: 3-8, 2005.
29. Jutabha P, Kanai Y, Hosoyamada M, Chairoungdua A, Kim do K, Iribe Y, Babu E, Kim JY, Anzai N, Chatsudthipong V, and Endou H. Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule. J Biol Chem 278: 27930-27938, 2003.
30. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, and Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41: 1287-1293, 2003.
31. 1) in vascular endothelial cells and smooth muscle cells (Abstract). J Am Soc Nephrol 14: 136A, 2003.
32. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, and Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13: 2888-2897, 2002.
33. Khosla U, Zharikov S, Finch J, Nakagawa T, Roncal C, Mu W, Krotova K, Block E, Prabhakar S, and Johnson R. Hyperuricemia induces endothelial dysfunction. Kidney Int 2004.
34. Kikuchi Y, Koga H, Yasutomo Y, Kawabata Y, Shimizu E, Naruse M, Kiyama S, Nonoguchi H, Tomita K, Sasatomi Y, and Takebayashi S. Patients with renal hypouricemia with exercise-induced acute renal failure and chronic renal dysfunction. Clin Nephrol 53: 467-472, 2000.
35. Koepsell H and Endou H. The SLC22 drug transporter family. Pflügers Arch 447: 666-676, 2004.
36. Lipkowitz MS, Leal-Pinto E, Cohen BE, and Abramson RG. Galectin 9 is the sugar-regulated urate transporter/channel UAT. Glycoconj J 19: 491-498, 2004.
37. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, and Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106, 2001.
38. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, and Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: F991-F997, 2002.
39. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, and Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 282: 991-997, 2002.
40. Nakagawa T, Mazzali M, Kang DH, Kanellis J, Watanabe S, Sanchez-Lozada LG, Rodriguez-Iturbe B, Herrera-Acosta J, and Johnson RJ. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 23: 2-7, 2003.
41. Perheentupa J and Raivio K. Fructose-induced hyperuricaemia. Lancet 2: 528-531, 1967.
42. Price KL, Mu W, Raines EW, Long D, Endou H, and Johnson RJ. Expression of a urate transporter in human vascular smooth muscle cells (Abstract). J Am Soc Nephrol 14: 145A, 2003.
43. Rampoldi L, Caridi G, Santon D, Boaretto F, Bernascone I, Lamorte G, Tardanico R, Dagnino M, Colussi G, Scolari F, Ghiggeri GM, Amoroso A, and Casari G. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 12: 3369-3384, 2003.
44. Rao GN, Corson MA, and Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266: 8604-8608, 1991.
45. Roch-Ramel F and Guisan B. Renal transport of urate in humans. News Physiol Sci 14: 80-84, 1999.
46. Saito I, Saruta T, Kondo K, Nakamura R, Oguro T, Yamagami K, Ozawa Y, and Kato E. Serum uric acid and the renin-angiotensin system in hypertension. J Am Geriatr Soc 26: 241-247, 1978.
47. Simoyi MF, Van Dyke K, and Klandorf H. Manipulation of plasma uric acid in broiler chicks and its effect on leukocyte oxidative activity. Am J Physiol Regul Integr Comp Physiol 282: R791-R796, 2002.
48. Sorensen LB. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum 8: 694-706, 1965.
49. Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, Arru G, and Rosati G. Serum uric acid and multiple sclerosis. Neurol Sci 23: 183-188, 2002.
50. Stirpe F, Della CE, Bonetti E, Abbondanza A, Abbati A, and De SF. Fructose-induced hyperuricaemia. Lancet 2: 1310-1311, 1970.
51. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 349: 1647-1655, 2003.
52. Terkeltaub R. Gout and hyperuricemia. In: Internal Medicine, edited by Stein JH, Klippel JH, Reynolds HY, Eisenberg JM, Hutton JJ, Kohler PO, LaRusso NF, O'Rourke RA, Samuels MA, Sande MA, and Zvaifler NJ. St. Louis, MO: Mosby, 1998.
53. Toncev G, Milicic B, Toncev S, and Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9: 221-226, 2002.
54. Van Aubel RA, Smeets PH, Peters JG, Bindels RJ, and Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13: 595-603, 2002.
55. Van Aubel RA, Smeets PH, van den Heuvel JJ, and Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 288: F327-F333, 2004.
56. Volk KJ, Lee MS, Yost RA, and Brajter-Toth A. Electrochemistry/ thermospray/tandem mass spectrometry in the study of biooxidation of purines. Anal Chem 60: 720-722, 1988.
57. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, and Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40: 355-360, 2002.
58. Wu XW, Lee CC, Muzny DM, and Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci USA 86: 9412-9416, 1989.
59. Wu XW, Muzny DM, Lee CC, and Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 34: 78-84, 1992.